Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAG regimen in unfit newly diagnosed AML
ChiCTR2200063954Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine, venetoclax and filgrastim in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Composite complete remission rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
azacitidinevenetoclaxfilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200063954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063954.